Axerovision Is Developing Novel Therapies For The Treatment Of Ophthalmic Inflammatory Diseasessuch As Dry Eye Diseasededand Meibomian Gland Dysfunctionmgdaxr 159 Is Being Developed For The Treatment Of Chronic Ded Axr 270 Is Being Developed For The Short Term Treatment Of Ded Both Assets Have Achieved Clinical Proof Of Concept
No conferences found for this company.
| Company Name | Axerovision Inc |
| Country |
United States
|
| Address | N/A |
| Telephone | N/A |
| N/A |
Enter your address and we will specify the offer for your area.